

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier**Product Name** Namenda**Other means of identification****Product Code** FG00080**Synonyms** Memantine Hydrochloride**Recommended use of the chemical and restrictions on use****Recommended Use** Alzheimer's

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

Details of the supplier of the safety data sheet**Manufacturer**

Allergan plc
5 Giralda Farms
Madison, NJ USA 07940
+1-800-272-5525

E-mail address SDS@Allergan.com**Emergency telephone number****Emergency Telephone**

Call CHEMTREC Day or Night
Within USA or Canada: 1-800-424-9300
Outside USA and Canada: +1-703-741-5970 (collect calls accepted)

2. HAZARDS IDENTIFICATION

Classification**OSHA Regulatory Status**

This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

Acute toxicity - Inhalation (Dusts/Mists)

Category 4

Label elements**Emergency Overview****Warning****Hazard statements**

H332 - Harmful if inhaled



Appearance Tablet	Physical state Solid	Odor No information available
Chemical Name Memantine Hydrochloride	Symptoms Most common are dizziness, headache, confusion and constipation	
Chemical Name Memantine Hydrochloride	Medical Conditions Aggravated by Exposure Contraindication include hypersensitivity to any component of this product hepatic impairment	

Precautionary statements

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray

P271 - Use only outdoors or in a well-ventilated area

P304 + P340 - IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing

P312 - Call a POISON CENTER or doctor if you feel unwell

Other Information

Unknown Acute Toxicity

52% of the mixture consists of ingredient(s) of unknown toxicity

Over the counter drugs in their solid form are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 20 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limit may be surpassed, than can be considered hazardous

3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS No.	EINECS	Weight-%
CROSCARMELLOSE SODIUM NF(TYPE A, AC-DI-SOL)	74811-65-7	N/A	30 - 60*
MICROCRYSTALLINE CELLULOSE(AVICEL PH102)	9004-34-6	232-674-9	10 - 30*
SILICON DIOXIDE NF(SYLOID 244FP)	7631-86-9	231-545-4	10 - 30*
UREA USP	57-13-6	200-315-5	1 - 5*
Tetracycline	60-54-8	200-481-9	1 - 5*
Sodium salicylate	54-21-7	200-198-0	1 - 5*
Pirenoxine	1043-21-6	213-872-4	1 - 5*
Memantine Hydrochloride	41100-52-1	255-219-6	1 - 5*
Asenapine	85650-56-2	288-064-8	1 - 5*
Abicipar	1327278-94-3	N/A	1 - 5*
TALC USP(1656)	14807-96-6	238-877-9	1 - 5*
Tropium Chloride	10405-02-4	233-875-4	0.1 - 1*
Titanium Dioxide	1317-70-0	215-280-1	0.1 - 1*
LACTOSE MONOHYDRATE NF(FAST FLOW)(SPRAY DRIED)	64044-51-5	N/A	0.1 - 1*
POVIDONE USP(PLASDONE K-29-32)	9003-39-8	N/A	<0.1*
MAGNESIUM STEARATE NF(VEGETABLE SOURCE)	557-04-0	209-150-3	<0.1*
Sucrose Palmitate	26446-38-8	247-706-7	<0.1*
STEARIC ACID NF	57-11-4	200-313-4	<0.1*
PWDRD CELLULOSE BW40 NF	9004-32-4	N/A	<0.1*
FERRIC OXIDE NF (RED 30)	1309-37-1	215-168-2	<0.1*
COLLOIDAL SILICON DIOXIDE(CAB-O-SIL GRADE M-5P)	112945-52-5	N/A	<0.1*
POLYETHYLENE GLYCOL NF6000	25833-68-3	N/A	<0.1*
CORN STARCH NF	9005-25-8	232-679-6	<0.1*
White Cresin Wax	8002-74-2	232-315-6	<0.1*
CARNABUA WAX NF	8015-86-9	232-399-4	<0.1*

*The exact percentage (concentration) of composition has been withheld as a trade secret.

4. FIRST AID MEASURES

First aid measures

General advice	If symptoms persist, call a physician. Do not breathe dust/fume/gas/mist/vapors/spray. Do not get in eyes, on skin, or on clothing.
Eye contact	Immediately flush with plenty of water. After initial flushing, remove any contact lenses and continue flushing for at least 15 minutes. Keep eye wide open while rinsing. If symptoms persist, call a physician.
Skin Contact	Consult a physician if necessary. Wash off immediately with soap and plenty of water while removing all contaminated clothes and shoes.
Inhalation	Remove to fresh air. Call a physician. If breathing is irregular or stopped, administer artificial respiration. Avoid direct contact with skin. Use barrier to give mouth-to-mouth resuscitation.
Ingestion	Rinse mouth. Drink plenty of water. If symptoms persist, call a physician. Do NOT induce vomiting.

Chemical Name
Memantine Hydrochloride

Note to physicians
Conditions that raise urine pH may decrease urinary elimination of Memantine, resulting in increased plasma levels of memantine.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media

None known.

Specific hazards arising from the chemical

Fire may produce irritating, corrosive and/or toxic gases.

Explosion data

Sensitivity to Mechanical Impact Not impact sensitive.

Sensitivity to Static Discharge Fine dust dispersed in air, in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.

Protective equipment and precautions for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions	Use personal protection recommended in Section 8. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing.
Environmental precautions	Prevent entry into waterways, sewers, basements or confined areas. Do not flush into surface water or sanitary sewer system. See Section 12 for additional ecological information.
Methods for containment	Prevent further leakage or spillage if safe to do so.
Methods for cleaning up	Use personal protective equipment as required. Cover powder spill with plastic sheet or tarp to minimize spreading and keep powder dry. Take up mechanically, placing in appropriate containers for disposal. Avoid creating dust. Clean contaminated surface thoroughly.

7. HANDLING AND STORAGE

Advice on safe handling Avoid contact with skin, eyes or clothing. Use personal protective equipment as required. Wash contaminated clothing before reuse. Do not breathe dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using this product.

Storage Conditions Keep container tightly closed in a dry and well-ventilated place. Keep out of the reach of children.

Incompatible materials None known based on information supplied.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure Guidelines

Chemical Name	ACGIH TLV	OSHA PEL	NIOSH IDLH	Allergan OEL (ug/m ³)
MICROCRYSTALLINE CELLULOSE(AVICEL PH102) 9004-34-6	TWA: 10 mg/m ³	TWA: 15 mg/m ³ total dust TWA: 5 mg/m ³ respirable fraction (vacated) TWA: 15 mg/m ³ total dust (vacated) TWA: 5 mg/m ³ respirable fraction (vacated) TWA: 5 mg/m ³ (vacated) STEL: 10 mg/m ³	TWA: 10 mg/m ³ total dust TWA: 5 mg/m ³ respirable dust TWA: 1 mg/m ³	N/A
SILICON DIOXIDE NF(SYLOID 244FP) 7631-86-9	N/A	(vacated) TWA: 6 mg/m ³ <1% Crystalline silica TWA: 20 mppcf : (80)/(% SiO ₂) mg/m ³ TWA	IDLH: 3000 mg/m ³ TWA: 6 mg/m ³	N/A
Tetracycline 60-54-8	N/A	N/A	N/A	250.00
Memantine Hydrochloride 41100-52-1	N/A	N/A	N/A	67
Asenapine 85650-56-2	N/A	N/A	N/A	2
TALC USP(1656) 14807-96-6	TWA: 2 mg/m ³ particulate matter containing no asbestos and <1% crystalline silica, respirable particulate matter	(vacated) TWA: 2 mg/m ³ respirable dust <1% Crystalline silica, containing no Asbestos TWA: 20 mppcf if 1% Quartz or more;use Quartz limit	IDLH: 1000 mg/m ³ TWA: 2 mg/m ³ containing no Asbestos and <1% Quartz respirable dust	N/A
Trospium Chloride 10405-02-4	N/A	N/A	N/A	100 ug/m ³
MAGNESIUM STEARATE NF(VEGETABLE SOURCE) 557-04-0	TWA: 10 mg/m ³ inhalable particulate matter TWA: 3 mg/m ³ respirable particulate matter TWA: 10 mg/m ³ inhalable particulate matter except stearates of toxic metals TWA: 3 mg/m ³ respirable particulate matter except stearates of toxic metals	N/A	N/A	N/A
STEARIC ACID NF 57-11-4	TWA: 10 mg/m ³ inhalable particulate matter TWA: 3 mg/m ³ respirable particulate matter	N/A	N/A	N/A
FERRIC OXIDE NF (RED 30) 1309-37-1	TWA: 5 mg/m ³ respirable particulate matter	TWA: 10 mg/m ³ fume TWA: 15 mg/m ³ total dust TWA: 5 mg/m ³ respirable fraction (vacated) TWA: 10 mg/m ³ fume and total dust Iron oxide (vacated) TWA: 5 mg/m ³ respirable fraction regulated under Rouge	IDLH: 2500 mg/m ³ Fe dust and fume TWA: 5 mg/m ³ Fe dust and fume	N/A
CORN STARCH NF	TWA: 10 mg/m ³	TWA: 15 mg/m ³ total dust	TWA: 10 mg/m ³ total dust	N/A

9005-25-8		TWA: 5 mg/m ³ respirable fraction (vacated) TWA: 15 mg/m ³ total dust (vacated) TWA: 5 mg/m ³ respirable fraction	TWA: 5 mg/m ³ respirable dust	
White Cresin Wax 8002-74-2	TWA: 2 mg/m ³ fume	(vacated) TWA: 2 mg/m ³	TWA: 2 mg/m ³ fume	N/A

NIOSH IDLH *Immediately Dangerous to Life or Health*

Other Information Vacated limits revoked by the Court of Appeals decision in AFL-CIO v. OSHA, 965 F.2d 962 (11th Cir., 1992).

Appropriate engineering controls

Engineering Controls The health hazard risks of handling this material are dependent on factors, such as physical form and quantity. Site specific risk assessments should be conducted to determine the appropriate exposure control measures. Good general ventilation should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Individual protection measures, such as personal protective equipment

Eye/face protection No eye protection is normally needed during medical administration of this product. During operations in which dusts of the product may be generated, safety glasses should be considered.

Skin and body protection During medical administration of this product, medical latex or nitrile gloves should be worn to avoid absorption of the product. Use appropriate protective clothing for the task (e.g., lab coat, etc.).

Respiratory protection Respiratory protection is generally not needed during routine conditions of use of this product. If respiratory protection is needed, use only respiratory protection authorized under appropriate regional regulations.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state	Solid	Appearance	Tablet
Color	No information available	Odor	No information available
Odor threshold	No information available		

Property	Values
pH	No information available
Melting point/freezing point	No information available
Boiling point / boiling range	No information available
Flash point	No information available
Evaporation rate	No information available
Flammability (solid, gas)	No information available
Flammability Limit in Air	
Upper flammability limit:	No information available
Lower flammability limit:	No information available
Vapor pressure	No information available
Vapor density	No information available
Specific Gravity	No information available
Water solubility	No information available
Solubility in other solvents	No information available
Partition coefficient	No information available
Autoignition temperature	No information available

Decomposition temperature No information available
 Explosive properties No information available
 Oxidizing properties No information available

Other Information

Molecular weight No information available
 VOC Content (%) No information available
 Density No information available
 Bulk density No information available

10. STABILITY AND REACTIVITY

Reactivity

Not defined As Reactive substance

Chemical stability

Stable under normal conditions.

Possibility of Hazardous Reactions

None under normal processing.

Conditions to avoid

Aerosol formation.

Incompatible materials

None known based on information supplied.

Hazardous Decomposition Products

None known based on information supplied.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure**Acute toxicity**

Chemical Name	Inhalation	Eye contact	Skin Contact	Ingestion
Tetracycline	Irritating to respiratory system.	Irritating to eyes.	Irritating to skin.	See Symptoms for more information.
Pirenoxine	See Symptoms for more information.	Eye contact may result in redness, pain or severe eye damage. Inhalation may cause irritation of the lungs and respiratory system.	Skin contact may result in inflammation characterized by itching, scaling, reddening, blistering, pain or dryness.	May cause irritation.
Asenapine	Move to fresh air. If symptoms persist, call a physician.	See Symptoms for more information.	See Symptoms for more information.	See Symptoms for more information.
Trospium Chloride	If airborne dusts generated by this product are inhaled, remove victim to fresh air. If necessary, use artificial respiration to support vital functions. Seek medical attention if adverse effect continues after removal to fresh air.	Contact with the eyes of airborne dusts generated by this compound may cause mild to moderate irritation, redness, and tearing (mechanical irritation).	In therapeutic use, this compound has caused swelling of the skin, rash and anaphylactic reactions. Angioedema of the face, lips, tongue and/or larynx has been reported with therapeutic use of Trospium. Angioedema associated with upper airway swelling may be life threatening. May cause irritation to skin. Prolonged or repeated skin contact may cause dermatitis (dry, red skin).	If this compound is swallowed, CALL PHYSICIAN OR POISON CONTROL CENTER FOR MOST CURRENT INFORMATION. If professional advice is not available, do not induce vomiting. Rinse mouth with water immediately. Victim should drink large quantities of water. If milk is available, victim should drink it after drinking water. Never induce vomiting or give diluents (milk or water) to someone who is unconscious, having convulsions, or unable to swallow.

Chemical Name	Oral LD50	Dermal LD50	Inhalation LC50
MICROCRYSTALLINE CELLULOSE(AVICEL PH102)	> 5 g/kg (Rat)	> 2 g/kg (Rabbit)	> 5800 mg/m ³ (Rat) 4 h
SILICON DIOXIDE NF(SYLOID 244FP)	> 5000 mg/kg (Rat)	> 2000 mg/kg (Rabbit)	> 2.2 mg/L (Rat) 1 h
UREA USP	= 8471 mg/kg (Rat)	N/A	N/A
Tetracycline	= 807 mg/kg (Rat)	N/A	N/A
Sodium salicylate	= 930 mg/kg (Rat)	N/A	N/A
Pirenoxine	>10,000 mg/kg Oral Rat	N/A	N/A
Memantine Hydrochloride	328 mg/kg Oral Rat (Female)	N/A	N/A
Tropium Chloride	= 1510 mg/kg (Rat)	N/A	N/A
POVIDONE USP(PLASDONE K-29-32)	= 100 g/kg (Rat)	N/A	N/A
STEARIC ACID NF	= 4600 mg/kg (Rat)	> 5 g/kg (Rabbit)	N/A
PWDRD CELLULOSE BW40 NF	= 27000 mg/kg (Rat)	> 2 g/kg (Rabbit)	> 5800 mg/m ³ (Rat) 4 h
FERRIC OXIDE NF (RED 30)	> 10000 mg/kg (Rat)	N/A	N/A
COLOIDAL SILICON DIOXIDE(CAB-O-SIL GRADE M-5P)	= 3160 mg/kg (Rat)	N/A	N/A
White Cresin Wax	> 5000 mg/kg (Rat)	> 3600 mg/kg (Rabbit)	N/A

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Chemical Name	Germ cell mutagenicity	Carcinogenicity	Reproductive toxicity	Effects on or via lactation
Tetracycline	Mutagenicity tests have not been conducted, however, positive results in vitro mammalian cell assays have been reported for related anti-bacterial drugs (tetracycline).	Animal studies in mice and rats have not shown carcinogenicity.	The therapeutic use of tetracyclines during the last half of pregnancy may cause permanent discoloration of teeth, incomplete development or lack of enamel, and inhibition of skeletal growth in the fetus. Fatty infiltration of the liver, leading to damage or failure, may occur in pregnant women.	No information available
Sodium salicylate	Not Suspected of being a Mutagen.	This product does not contain any carcinogens or potential carcinogens as listed by OSHA, IARC or NTP.	No information available.	This product is excreted in human breast milk. There is a potential for serious adverse effects in a nursing infant. Patient should stop nursing if this product is being used due to the potential for serious adverse effects to the nursing infant.
Pirenoxine	No information available.	Not listed by IARC, NTP, or USOSHA.	No information available.	No information available
Memantine Hydrochloride	Not mutagenic in the standard battery of tests.	Animal studies in mice and rats have not shown carcinogenicity.	Studies in rats have not shown fertility impairment. Decreased pup weights and an increase in incompletely ossified vertebrae was observed at slightly maternally toxic doses with the NOEL of approximately 3 times the maximum recommended human therapeutic dose.	It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this drug is administered to nursing mothers.
Asenapine	Negative for genotoxicity in vitro and in vivo tests.	Chronic Exposure or Carcinogenicity/ In a lifetime carcinogenicity study in CD-1 mice asenapine was administered subcutaneously at doses up to those resulting in plasma levels (AUC) estimated to be	Not teratogenic in rats or rabbits. Studies in rats have not shown fertility impairment. increases in post-implantation loss and early pup deaths were seen at all doses, and decreases in subsequent pup survival	No information available

		5 times those in humans receiving the maximum recommended human dose (MRHD) of 10 mg twice daily. The incidence of malignant lymphomas was increased in female mice, with a no-effect dose resulting in plasma levels estimated to be 1.5 times those in humans receiving the MRHD. The mouse strain used has a high and variable incidence of malignant lymphomas, and the significance of these results to humans is unknown. There were no increases in other tumor types in female mice. In male mice, there were no increases in any tumor type.	and weight gain were seen at the two higher doses in rats.	
Trospium Chloride	Not mutagenic in the standard battery of tests.	Animal studies in mice and rats have not shown carcinogenicity.	Studies in rats and rabbits have not shown statistically significant levels of teratogenicity or harm to the fetus.	Detectable amounts of this compound have been identified in the milk of nursing women receiving this drug. Caution should be exercised when taking this compound is administered to nursing women.
POVIDONE USP(PLASDONE K-29-32)	No information available.	Not suspected of being a human carcinogen.	No information available.	No information available

Target Organ Effects Central nervous system, Central Vascular System (CVS), Eyes, Respiratory system, Skin.

Numerical measures of toxicity - Product Information

Unknown Acute Toxicity 52% of the mixture consists of ingredient(s) of unknown toxicity

The following values are calculated based on chapter 3.1 of the GHS document .

- ATEmix (oral) 2646 mg/kg
- ATEmix (dermal) 2135 mg/kg
- ATEmix (inhalation-dust/mist) 1.2 mg/l

12. ECOLOGICAL INFORMATION

Ecotoxicity

79% of the mixture consists of component(s) of unknown hazards to the aquatic environment

Chemical Name	Algae/aquatic plants	Fish	Crustacea
SILICON DIOXIDE NF(SYLOID 244FP) 7631-86-9	440: 72 h Pseudokirchneriella subcapitata mg/L EC50	5000: 96 h Brachydanio rerio mg/L LC50 static	7600: 48 h Ceriodaphnia dubia mg/L EC50
UREA USP 57-13-6	N/A	16200 - 18300: 96 h Poecilia reticulata mg/L LC50	10000: 24 h Daphnia magna Straus mg/L EC50 3910: 48 h Daphnia magna mg/L EC50 Static
Tetracycline 60-54-8	Avoid release into the environment. Runoff from fire control or dilution water may cause pollution.	220	N/A
Sodium salicylate 54-21-7	N/A	1270 - 1470: 96 h Pimephales promelas mg/L LC50 flow-through	N/A
TALC USP(1656) 14807-96-6	N/A	100: 96 h Brachydanio rerio g/L LC50 semi-static	N/A

Chemical Name	Persistence and degradability	Bioaccumulation	Mobility	Partition coefficient
UREA USP	N/A	N/A	N/A	-1.59

57-13-6				
Sodium salicylate 54-21-7	N/A	N/A	N/A	2.26
Memantine Hydrochloride 41100-52-1	N/A	Based on the BCF, the potential for bioaccumulation in aquatic organisms is high.	Low mobility in soil	3.28
Asenapine 85650-56-2	N/A	Based on the BCF, the potential for bioaccumulation in aquatic organisms is high.	Immobile	4.77
Trospium Chloride 10405-02-4	No information available	No information available	No information available	Log P = 0.70

Other adverse effects No information available

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Disposal of wastes Disposal should be in accordance with applicable regional, national and local laws and regulations.

Contaminated packaging Do not reuse container. Dispose of contents/containers in accordance with local regulations.

14. TRANSPORT INFORMATION

DOT Not regulated

TDG Not regulated

ICAO (air) Not regulated

IATA Not regulated

IMDG Not regulated

ADR Not regulated

ADN Not regulated

15. REGULATORY INFORMATION

International Inventories

TSCA Not Listed
DSL/NDSL Not Listed
EINECS/ELINCS Not Listed

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

US Federal Regulations

Carcinogenicity The table below indicates whether each agency has listed any ingredient as a carcinogen. This product contains one or more substances which are classified by IARC as carcinogenic to humans (Group I), probably carcinogenic to humans (Group 2A) or possibly carcinogenic to humans (Group 2B)

Chemical Name	ACGIH	IARC	NTP	OSHA
---------------	-------	------	-----	------

MICROCRYSTALLINE CELLULO(AVICEL PH102) 9004-34-6	-	Group 1	Known	X
SILICON DIOXIDE NF(SYLOID 244FP) 7631-86-9	-	Group 3	-	-
TALC USP(1656) 14807-96-6	-	Group 3	-	X
POVIDONE USP(PLASDONE K-29-32) 9003-39-8	-	Group 3	-	-
FERRIC OXIDE NF (RED 30) 1309-37-1	-	Group 3	-	-
COLOIDAL SILICON DIOXIDE(CAB-O-SIL GRADE M-5P) 112945-52-5	-	Group 3	-	-

IARC (International Agency for Research on Cancer)
Not classifiable as a human carcinogen

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372

SARA 311/312 Hazard Categories

Acute health hazard	Yes
Chronic Health Hazard	No
Fire hazard	No
Sudden release of pressure hazard	No
Reactive Hazard	No

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42)

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material

US State Regulations

California Proposition 65

This product does not contain any Proposition 65 chemicals

Chemical Name	California Proposition 65
MICROCRYSTALLINE CELLULO(AVICEL PH102) - 9004-34-6	Carcinogen
Tetracycline - 60-54-8	Developmental

U.S. State Right-to-Know Regulations

Chemical Name	New Jersey	Massachusetts	Pennsylvania
MICROCRYSTALLINE CELLULO(AVICEL PH102) 9004-34-6	X	X	X
SILICON DIOXIDE NF(SYLOID 244FP) 7631-86-9	-	X	X
TALC USP(1656) 14807-96-6	X	X	X

16. OTHER INFORMATION

Revision Date 02-Oct-2018

Revision Note

No information available

Disclaimer

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

End of Safety Data Sheet